Vcare 2023 Annual Review
Published Time:
2024-02-07 17:49
Source:
I. Important Progress in Innovative Drug R&D
① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke.
② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months.
③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety.
Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
II. CRO/CDMO Service Revenue
2023 external service revenue: ~RMB 400 million (+25.5% YoY); New contracts: >RMB 550 million (+16.1% YoY).
III. Production Base Development
① Tianshu Pharmaceutical Phase I facility operational: 240+ employees; Robust quality system established; Passed 30+ audits by global clients/regulators; Monthly output exceeded RMB 10M since July trial production, reaching RMB 35M in December.
② Obtained Drug Manufacturing Certificate: enabling compliant API and innovative drug CDMO production.
IV. Corporate Financing
Closed Series C financing >RMB 450 million amid market downturn: Named among 2023 Top 10 Pharma Financing Projects in China; Total financing 2021-2023: ~RMB 1B; Valuation >RMB 3B.
V. Employee Care
① Organized 6 cultural events
② Held 12 Happy Hour activities
③ Completed 60+ promotions & 80+ internal trainings
④ 60+ employees received 3rd equity incentive
VI. Awards & Honors
Jiangsu Vcare Honored As: Jiangsu Provincial Enterprise Technology Center; Jiangsu Science & Technology Second Prize
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; High-Tech Enterprise; Nanjing Innovative SME
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn